The effectiveness and value of novel acute treatments for migraine.
J Manag Care Spec Pharm
; 26(11): 1456-1462, 2020 Nov.
Article
in En
| MEDLINE
| ID: mdl-33119447
ABSTRACT
DISCLOSURES Funding for this summary was contributed by Arnold Ventures, California Health Care Foundation, Harvard Pilgrim Health Care, and Kaiser Foundation Health Plan to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER's annual policy summit is supported by dues from Aetna, America's Health Insurance Plans, Anthem, Allergan, Alnylam, AstraZeneca, Biogen, Blue Shield of CA, Boehringer-Ingelheim, Cambia Health Services, CVS, Editas, Express Scripts, Genentech/Roche, GlaxoSmithKline, Harvard Pilgrim, Health Care Service Corporation, HealthFirst, Health Partners, Johnson & Johnson (Janssen), Kaiser Permanente, LEO Pharma, Mallinckrodt, Merck, Novartis, National Pharmaceutical Council, Pfizer, Premera, Prime Therapeutics, Regeneron, Sanofi, Spark Therapeutics, and United Healthcare. Agboola, Borrelli, Rind, and Pearson are employed by ICER. Touchette, through the University of Illinois at Chicago, received funding from ICER for development of the economic model described in this publication. Atlas has nothing to disclose.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Calcitonin Gene-Related Peptide
/
Receptors, Serotonin
/
Serotonin 5-HT1 Receptor Agonists
/
Analgesics
/
Migraine Disorders
Type of study:
Diagnostic_studies
/
Prognostic_studies
/
Systematic_reviews
Aspects:
Patient_preference
Limits:
Humans
Language:
En
Journal:
J Manag Care Spec Pharm
Year:
2020
Document type:
Article
Affiliation country:
Marruecos